Trending
Stocks.org
You are at:»»Pharma Movers: Agile Therapeutics Inc(NASDAQ:AGRX), Pernix Therapeutics Holdings Inc(NASDAQ:PTX), Prima Biomed Ltd.(NASDAQ:PBMD), Cerulean Pharma Inc(NASDAQ:CERU)

Pharma Movers: Agile Therapeutics Inc(NASDAQ:AGRX), Pernix Therapeutics Holdings Inc(NASDAQ:PTX), Prima Biomed Ltd.(NASDAQ:PBMD), Cerulean Pharma Inc(NASDAQ:CERU)

743
By on BioPharma

Agile Therapeutics Inc(NASDAQ:AGRX) shot higher Monday in a possible delayed reaction to Friday’s 14-year patent protection extension on Twirla, its contraceptive patch currently in Phase 3 clinical development. Specifically, the patent strengthens AGRX’s proprietary Skinfusion transdermal technology used in Twirla. 

Agile Therapeutics (NASDAQ:AGRX) went public at $6 per share on May 23. Since then analysts have marched steadily forward with positive ratings and price targets in the $17 – $18 per share range, suggesting shares could add at least another 60% from currents levels. 

AGRX is up 36.6% at $10.37 per share in afternoon Monday trading on 1.5 million shares, almost 5 times average daily volume. Shares hit a one-month high of $12.53 per share. 

Pernix Therapeutics Holdings Inc(NASDAQ:PTX) has appointed Sanjy Patel as chief financial officer of the specialty pharmaceutical company. 

Patel comes from outside the company, having previously worked in investment banking, and with the Clinton Foundation, negotiating and implementing long-term supply agreements for HIV and malaria drugs.  Pernix CEO Doug Drysdale said “Sanjay’s finance and investment banking credentials will provide valuable support as we seek to acquire additional specialty products and businesses.”  Shares of PTX are more than 1% higher on Monday to a two-year high of $8.75.

Prima Biomed Ltd.(NASDAQ:PBMD) reported Monday that a research article on its phase 2 single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer was published in the Journal for ImmunoTherapy of Cancer. The development helped support a share gain in Monday’s session. 

The research paper relates to the Company’s CAN-002 clinical trial of CVac in 28 patients with advanced epithelial ovarian cancer.  In afternoon trade, PBMD was off 0.88% to $1.12. 

Shares of Cerulean Pharma Inc(NASDAQ:CERU) gained 8%, regaining some lost ground from the previous session, when the clinical stage biopharmaceutical firm’s shares dove nearly 20%. 

Zacks reported at least one analyst has issued a negative revision in the past few weeks and Cerulean’s current year loss consensus among analysts also has moved wider over the last 30 days. Christopher Guiffre, J.D., the company’s chief business officer, is scheduled to, present at the JMP Securities Healthcare Conference on Tuesday. 

 

 

Get Free Updates and Stock Alerts!



*We only send one email per week
Share.

Related Posts

Get Winning Stock Alerts!

Our track record speaks for itself! Our last 7 alerts have delivered combined gains in excess of 300% and there are no signs of slowing down. Join UltimateStockAlerts.com now before you miss out on our next big runner!

We will never sell or share your information.
Close